Stephen Dressel

Steve has nearly 20 years of corporate finance and commercial experience. He joins from Dewpoint Therapeutics, where he was Senior Director, Financial Planning & Analysis responsible for overseeing budgeting, long-term planning, and analyses. Previously, he was Senior Director, Head of Corporate Planning & Operations at Akebia Therapeutics, a publicly traded, commercial-stage company that developed and marketed Auryxia®. Steve spent 10 years at Regeneron in finance roles with increasing responsibility rising to Director, Commercial Finance supporting Praulent and EYLEA, a top 5 biologic launch, where he developed and managed 10-year forecasts and $250 million budgets. He transitioned to commercial roles in the cardiometabolic franchise culminating as Director, Market Access Strategy. He began his career at Bio-IB, a life science-focused investment bank, where he helped execute financings, M&A, licensing, and corporate advisory assignments. Steve has his MBA from Fordham University and a BA degree from the University of Colorado.